Tostran 2% Gel

  • Name:

    Tostran 2% Gel

  • Company:
    info
  • Active Ingredients:

    Testosterone

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 07/02/20

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 7/2/2020

Click on this link to Download PDF directly

Kyowa Kirin Ltd

Kyowa Kirin Ltd

Company Products

Medicine NameActive Ingredients
Medicine Name Abstral Sublingual Tablets Active Ingredients fentanyl citrate
Medicine Name Chlorphenamine 10mg/ml solution for injection Active Ingredients Chlorphenamine Maleate
Medicine Name Crysvita solution for subcutaneous injection Active Ingredients Burosumab
Medicine Name Moventig 12.5 mg and 25 mg film-coated tablets Active Ingredients Naloxegol oxalate
Medicine Name Pabrinex Intravenous High Potency, Concentrate for Solution for Infusion Active Ingredients Ascorbic acid, Glucose Monohydrate, Nicotinamide, Pyridoxine Hydrochloride (Vitamin B6), Riboflavin sodium phosphate (Vitamin B2), Thiamine Hydrochloride (Vitamin B1)
Medicine Name POTELIGEO 4 mg/mL concentrate for solution for infusion Active Ingredients Mogamulizumab
Medicine Name Rectogesic 4 mg/g Rectal Ointment Active Ingredients Glyceryl Trinitrate
Medicine Name Thiopental Sodium 500 mg Powder for Solution for Injection Active Ingredients Thiopental Sodium
Medicine Name Tostran 2% Gel Active Ingredients Testosterone
Medicine Name Xomolix 2.5mg/ml solution for injection Active Ingredients Droperidol
1 - 0 of 10 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 7 February 2020 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 6 - date of revision

Free text change information supplied by the pharmaceutical company

Addition to Section 2. Warnings and precautions

Under 'Tell your doctor before treatment if you: - have or ever had blood clotting problems' the addition of the following bulleted text

- factors that increase your risk for blood clots in a vein: previous blood clots in a vein; smoking; obesity; cancer; immobility; if one of your immediate family has had a blood clot in the leg, lung or other organ at a young age (e.g. below the age of about 50); or as you get older.
How to recognise a blood clot: painful swelling of one leg or sudden change in colour of the skin e.g. turning pale, red or blue, sudden breathlessness, sudden unexplained cough which may bring up blood; or sudden chest pain, severe light headedness or dizziness, severe pain in your stomach, sudden loss of vision. Seek urgent medical attention if you experience one of these symptoms.

Date of revision of the text

Change from: 02/2019; to: 12/2019

 

Updated on 7 February 2020 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.4.  Special warnings and precautions for use

statement under the section clotting disorders expanded to include risk of VTE

Changed from:

Testosterone should be used with caution in patients with thrombophilia, as there have been post-marketing studies and reports of thrombotic events in these patients during testosterone therapy.

Changed to:

Testosterone should be used with caution in patients with thrombophilia or risk factors for venous thromboembolism (VTE), as there have been post-marketing studies and reports of thrombotic events (e.g. deep-vein thrombosis, pulmonary embolism, ocular thrombosis) in these patients during testosterone therapy.  In thrombophilic patients, VTE cases have been reported even under anticoagulation treatment, therefore continuing testosterone treatment after first thrombotic event should be carefully evaluated. In case of treatment continuation, further measures should be taken to minimise the individual VTE risk.

Section 10  Date of Revision of the Text

Changed from:

February 2019

Changed to:

December 2019

Updated on 6 June 2019 SmPC

Reasons for updating

  • Other

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 21 February 2019 PIL

Reasons for updating

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 20 February 2019 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 7 (Marketing Authorisation Holder)- updated to Kyowa Kirin Holdings B.V., Bloemlaan 2, 2132NP Hoofddorp, The Netherlands

Section 8- Marketing Authorisation Number updated to PA2288/001/004

Section 10- Date of revision updated to Feb 2019

Updated on 28 February 2017 SmPC

Reasons for updating

  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 10, Date of revision of the text has been changed from December 2016 to February 2017

Updated on 28 February 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 28 February 2017 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 28 February 2017 PIL

Reasons for updating

  • Change to section 6 - date of revision

Updated on 20 February 2017 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 4.4 (special warnings and precautions for use): The statement ' Clotting disorders- Testosterone should be used with caution in patients with thrombophilia, as there have been post-marketing studies and reports of thrombotic events in these patients during testosterone therapy.' has been added.$0$0$0$0In section 10: Date of revision of the text changed from May 2016 to December 2016.$0

Updated on 17 February 2017 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 6 - date of revision

Updated on 28 October 2016 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 7 (Marketing Authorisation Holder)- Name change from ProStrakan to Kyowa Kirin$0In section 10- Date of revision of the text changed from Aug 2015 to May 2016$0

Updated on 26 October 2016 PIL

Reasons for updating

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 17 December 2015 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

None provided

Updated on 16 December 2015 PIL

Reasons for updating

  • New PIL for medicines.ie